Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.40M | 200.00K | 200.00K | 1.73M | 1.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.40M | 200.00K | 200.00K | 1.73M | 1.85M |
| Cost of Revenue | 75.10M | 102.74M | 105.67M | 154.40M | 153.56M |
| Gross Profit | -73.70M | -102.54M | -105.47M | -152.66M | -151.71M |
| SG&A Expenses | -31.05M | 55.89M | 59.84M | 119.04M | 119.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.35M | 232.66M | 263.59M | 371.51M | 370.66M |
| Operating Income | -98.95M | -232.46M | -263.39M | -369.77M | -368.80M |
| Income Before Tax | -163.69M | 1.72B | 1.69B | 1.64B | 1.63B |
| Income Tax Expenses | 2.00K | 2.00K | 2.00K | -2.00K | 0.00 |
| Earnings from Continuing Operations | -163.69 | 1.72K | 1.69K | 1.64K | 1.63K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.69M | 1.72B | 1.69B | 1.64B | 1.63B |
| EBIT | -98.95M | -232.46M | -263.39M | -369.77M | -368.80M |
| EBITDA | -96.17M | -229.86M | -261.10M | -367.88M | -367.37M |
| EPS Basic | -10.58 | 118.37 | 115.39 | 111.57 | 110.01 |
| Normalized Basic EPS | -3.86 | -9.70 | -11.55 | -16.69 | -17.66 |
| EPS Diluted | -10.59 | 116.74 | 113.77 | 109.95 | 108.40 |
| Normalized Diluted EPS | -3.86 | -9.61 | -11.46 | -16.60 | -17.58 |
| Average Basic Shares Outstanding | 61.87M | 61.02M | 59.19M | 57.26M | 53.58M |
| Average Diluted Shares Outstanding | 61.87M | 61.21M | 59.38M | 57.44M | 53.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |